Onvitrelin ucalontide

DB19183InvestigationalProtein Based Therapies

Onvitrelin ucalontide is under investigation in clinical trial NCT01485848 (EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer).

Mechanism: Pharmacologically active on Gonadotropin-releasing hormone receptor
Curator reviewed
Also known as: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors) · Ep-100 (peptide) · Membrane-disrupting peptide ep-100
Code names: EP-100

Resolves to

Compound

UNIIUF1EL37E41CAS1620643-19-7

Targets

P30968GNRHR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Onvitrelin ucalontide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account